Berg K, Dahlén G, Frick MH. Lp(a) lipoprotein and pre-β1-lipoprotein in patients with coronary heart disease. Clin Genet John Wiley & Sons, Ltd. 1974;6:230–5.

CAS  Google Scholar 

Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.

CAS  PubMed  Article  Google Scholar 

Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol Am College Cardiol Foundation. 2022;79:757–68.

CAS  Article  Google Scholar 

• Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. 2018 Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3:619–27 This mendelian randomization used 43 genetic variants in the LPA gene region to determine the genetically predicted lowering Lp(a) effects on ASCVD. A 10-mg/dL lower predicted Lp(a) concentration was associated with a 5.8% lower ASCVD risk. Moreover, to match the ASCVD risk benefit from 1 mmol/l (38.67 mg/dl) LDL-C lowering, an estimated 102 mg/dl (213 nmol/l) reduction in Lp(a) will be needed.

PubMed  PubMed Central  Article  Google Scholar 

Tipping RW, Ford CE, Simpson LM, Walldius G, Jungner I, Folsom AR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA - J Am Med Assoc. 2009;302:412–23.

Article  Google Scholar 

Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–53.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. Am College Cardiol Foundation. 2019;74:54–66.

CAS  Article  Google Scholar 

Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA - J Am Med Assoc. 2009;301:2331–9.

CAS  Article  Google Scholar 

Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40:2760–70.

CAS  PubMed  Article  Google Scholar 

Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. Am College Cardiol Foundation. 2014;63:470–7.

CAS  Article  Google Scholar 

Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16:305–18.

PubMed  Article  Google Scholar 

Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60:722–9.

CAS  PubMed  Article  Google Scholar 

Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J Lipid Res Am Soc Biochem Mole Biol. 2016;57:1953–75.

CAS  Google Scholar 

Maio S Di, Lamina C, Coassin S, Forer L, Würzner R, Schönherr S, et al. Lipoprotein(a) and SARS-CoV-2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events. J Intern Med. John Wiley & Sons, Ltd; 2021;n/a.

Gencer B, Kronenberg F, Stroes ES, Mach F. Lipoprotein(a): the revenant. Eur. Heart J. Oxford University Press; 2017;1553–60.

Chan DC, Pang J, Hooper AJ, Bell DA, Burnett JR, Watts GF. Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic? Clin Chem. 2019;65:1258–66.

CAS  PubMed  Article  Google Scholar 

Langsted A, Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol Elsevier. 2016;4:577–87.

CAS  Article  Google Scholar 

Speer T, Ridker PM, Von Eckardstein A, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J. 2021;42:2170–85.

CAS  PubMed  Article  Google Scholar 

Lin J, Reilly MP, Terembula K, Wilson FP. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS ONE. 2014;9:1–16.

Google Scholar 

Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res. 1997;38:1755–63.

CAS  PubMed  Article  Google Scholar 

Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int Elsevier Masson SAS. 2007;71:1036–43.

CAS  Article  Google Scholar 

Kostner KM, Kostner GM 2017 Lipoprotein (a): a historical appraisal. J Lipid Res. © THE AUTHORS. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology 2017;58:1–14.

Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;ehac056.

Nurmohamed NS, Kaiser Y, Schuitema PCE, Ibrahim S, Nierman M, Fischer JC, et al. Finding very high lipoprotein(a): the need for routine assessment. Eur J Prev Cardiol. 2021;

Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk. Circ Am Heart Assoc. 2014;129:635–42.

CAS  Google Scholar 

Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol Am Heart Assoc. 2020;40:255–66.

CAS  Article  Google Scholar 

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275–84.

CAS  PubMed  Article  Google Scholar 

de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2021;zwab171.

Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8:17887.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M, Group on behalf of L and BPM-AC (LBPMC). Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2018;78:453–62.

CAS  PubMed  Article  Google Scholar 

Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229–39.

CAS  PubMed  Google Scholar 

Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13:894–900.

PubMed  Article  Google Scholar 

Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC Focus Seminar 1/4. J Am Coll Cardiol Am College Cardiol Foundation. 2021;77:1564–75.

CAS  Article  Google Scholar 

Rubino J, MacDougall DE, Sterling LR, Kelly SE, McKenney JM, Lalwani ND. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: a randomized, controlled trial. J Clin Lipidol. 2021;15:593–601.

PubMed  Article  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med Massachusetts Med Soc. 2017;376:1713–22.

CAS  Article  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Massachusetts Medical Society. 2018;379:2097–107.

CAS  Article  Google Scholar 

Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al. The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation Am Heart Assoc. 2020;0:1600–7.

CAS  Google Scholar 

O’Donoghue ML, Sergio F, Giugliano RP, Stroes ESG, Estella K, Ioanna G-B, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circ Am Heart Assoc. 2019;139:1483–92.

CAS  Google Scholar 

Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41:4245–55.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med Massachusetts Med Soc. 2017;376:1430–40.

CAS  Article  Google Scholar 

Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med Massachusetts Med Soc. 2020;382:1520–30.

CAS  Article  Google Scholar 

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med Massachusetts Med Soc. 2020;382:1507–19.

CAS  Article  Google Scholar 

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet Elsevier Ltd. 2016;388:2239–53.

CAS  Article  Google Scholar 

• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med Massachusetts Med Soc. 2020;382:244–55. This phase-2b randomized, double-blind, placebo-controlled, dose-ranging trial with pelacarsen showed up to 80% reduction in Lp(a) plasma levels after 6 months of treatment with no safety concerns.

CAS  Article  Google Scholar 

• Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28:96–103. Findings of the phase 1 dose-escalation trial with siRNA olpasiran showed 97% reduction in Lp(a) levels without any serious adverse events in 64 individuals.

CAS  PubMed  Article  Google Scholar 

• Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC